NGM Biopharmaceuticals, Inc.

Gastrointestinal Program Seeking Drugs that Mimic the Bariatric
Surgery-Induced Remission of Diabetes

NGM has devised a novel strategy to identify potential drug targets that restore glucose balance in diabetic patients. Rather than a focus on alleviating individual symptoms, we seek transformational medicines that address the underlying disease state. This ambitious approach is empowered by an emerging human clinical observation, which offers new insights into human biology and the pathophysiology of diabetes: gastric bypass bariatric surgeries for the treatment of obesity have been shown to completely and persistently cure type 2 diabetes in the majority of patients who undergo these procedures. Remarkably, this effect is evident within days of surgery, long before any significant weight loss is achieved. While the underlying molecular mechanisms have yet to be determined, the gastrointestinal (GI) tract is known to play an important role in maintaining energy (and glucose) balance and comprises the largest hormone-producing organ in the body. Moreover, studies from both human patients and animal models have shown that the pattern of GI hormone secretion is significantly altered after gastric bypass surgery. NGM’s GI program, the Company’s principal focus, aims to elucidate the biology of these novel proteins and peptides, generating enticing new targets and potential breakthrough therapeutics for the treatment of type 2 diabetes.

Incredibly, many patients who have undergone gastric bypass surgery experience an improvement in health that extends far beyond the permanent remission of type 2 diabetes. In fact, several analyses of clinical data collected over the past several decades point to significant improvements in more than a dozen disease conditions, including dyslipidemia/hypercholesterolemia, cardiovascular disease, hypertension and cancer. Thus, a better understanding of the gastrointestinal endocrine system and the mechanisms driving the remarkable health benefits of gastric bypass surgery may provide an innovative path for discovering and developing novel therapies to treat a wide range of medical conditions. As the leading company in this area, NGM is well positioned to achieve this goal.

For additional information, please contact us at: info@ngmbio.com

Overview – Type 2 Diabetes Gastrointestinal Program Muscle Program		Gastrointestinal Program Gastrointestinal Program Seeking Drugs that Mimic the Bariatric Surgery-Induced Remission of Diabetes NGM has devised a novel strategy to identify potential drug targets that restore glucose balance in diabetic patients. Rather than a focus on alleviating individual symptoms, we seek transformational medicines that address the underlying disease state. This ambitious approach is empowered by an emerging human clinical observation, which offers new insights into human biology and the pathophysiology of diabetes: gastric bypass bariatric surgeries for the treatment of obesity have been shown to completely and persistently cure type 2 diabetes in the majority of patients who undergo these procedures. Remarkably, this effect is evident within days of surgery, long before any significant weight loss is achieved. While the underlying molecular mechanisms have yet to be determined, the gastrointestinal (GI) tract is known to play an important role in maintaining energy (and glucose) balance and comprises the largest hormone-producing organ in the body. Moreover, studies from both human patients and animal models have shown that the pattern of GI hormone secretion is significantly altered after gastric bypass surgery. NGM’s GI program, the Company’s principal focus, aims to elucidate the biology of these novel proteins and peptides, generating enticing new targets and potential breakthrough therapeutics for the treatment of type 2 diabetes. Incredibly, many patients who have undergone gastric bypass surgery experience an improvement in health that extends far beyond the permanent remission of type 2 diabetes. In fact, several analyses of clinical data collected over the past several decades point to significant improvements in more than a dozen disease conditions, including dyslipidemia/hypercholesterolemia, cardiovascular disease, hypertension and cancer. Thus, a better understanding of the gastrointestinal endocrine system and the mechanisms driving the remarkable health benefits of gastric bypass surgery may provide an innovative path for discovering and developing novel therapies to treat a wide range of medical conditions. As the leading company in this area, NGM is well positioned to achieve this goal. For additional information, please contact us at: info@ngmbio.com